Depo-Provera Brain Tumor Claims Expand

High-Dosage Unnecessary?

A 150 mg dose of Depo-Provera floods the bloodstream with synthetic progestin. Plaintiffs question Pfizer’s decision to continue using the higher 150 mg formula for decades, and  whether that level of exposure was necessary, pointing to lower-dose alternatives — such as Depo-SubQ Provera 104 — which achieve similar contraceptive effects with less hormone. The litigation alleges that continued reliance on the higher 150 mg formulation may have increased the risk of brain tumors, particularly intracranial meningiomas.

Unlike daily birth control pills, which can be stopped at any time, Depo-Provera remains in the body for about three months after each injection. This means the hormone stays at a steady level for an extended period. Plaintiffs argue that this longer exposure may be important in cases involving hormone-sensitive tumors, which can respond to changes in hormone levels. The lawsuits also question whether lower-dose options could have reduced potential risks while still providing effective birth control.

Depo-Provera Brain Tumor Complaint

One recent lawsuit was filed last month by Rondella Kay Wray, who alleges that she developed a brain tumor after years of using the hormone-based birth control shot. The lawsuit names Pfizer and related entities as defendants and asserts multiple causes of action, including failure to warn, design defect, negligence, and misrepresentation.

According to the complaint, Wray received Depo-Provera injections from approximately 2014 through 2020. She was subsequently diagnosed with an intracranial meningioma. The tumor is not surgically operable due to its location. Wray requires ongoing monitoring through MRI and CT imaging to assess tumor growth and associated risks. The complaint further alleges a continuing risk of neurological complications and the potential need for radiation or other treatment.

Failure-to-Warn Claims

Wray says that she would not have used Depo-Provera had adequate warnings been provided regarding the alleged risk of brain tumors. And thousands of plaintiffs echo her allegations:  Manufacturers did not sufficiently disclose the potential for Depo-Provera to cause or accelerate the growth of meningiomas.

Meningiomas are typically slow-growing tumors that may remain asymptomatic for extended periods. However, depending on size and location, they can interfere with brain tissue and neurological function and may require surgical intervention or long-term monitoring.

The complaints cite research, including a French study, indicating an increased risk of intracranial meningioma associated with prolonged exposure to certain progestin-based therapies.

Alleged Knowledge of Risk

Wray’s lawsuit also places emphasis on what manufacturers allegedly knew about the relationship between hormones and tumor development. The complaint states that evidence linking hormones like those used in Depo-Provera to brain tumor development dates has been known for decades. And since at least 1983, researchers have known that meningioma cells contain a high number of progesterone receptors, which respond to hormonal exposure.

According to the filing, manufacturers were aware of these findings prior to bringing Depo-Provera to market but did not provide warnings advising patients or physicians to monitor for early signs of brain tumor development. The lawsuit alleges that this omission allowed continued use of the product without adequate risk disclosure.

Key Legal Questions

The litigation is likely to center on several issues:

• Whether the association between Depo-Provera and meningioma risk is supported by reliable scientific evidence;
• Whether manufacturers had sufficient knowledge of that risk to trigger a duty to warn;
• Whether existing warnings were adequate; and
• Whether the product was unreasonably dangerous as marketed.

The resolution of these questions will determine the viability of individual claims, including Wray’s, as well as the broader trajectory of the litigation. For now,  Depo-Provera litigation remains in an active pretrial phase as discovery continues.

For plaintiffs such as Rondella Kay Wray, the claims rely on established product liability theories applied to evolving scientific evidence. For defendants, the focus is expected to remain on causation, regulatory compliance, and the adequacy of existing warnings.

Further developments are likely as courts evaluate expert testimony and assess the scientific basis of the alleged link between Depo-Provera and intracranial meningiomas.